All In Biotech

Drug Trial Radar · NCT07611110

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

A Phase III, Multicentre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI-2265) ²²⁵Ac-PSMA-I&T Compared With Standard of Care in Patients With PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 670 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

670

Planned (sponsor's estimate)

Start

May 4, 2026

Primary completion

Jun 4, 2029

Study completion Jun 6, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])Drug

    IV

  • CabazitaxelDrug

    IV in combination with oral prednisone/prednisolone

  • AbirateroneDrug

    Oral in combination with prednisone/prednisolone

  • EnzalutamideDrug

    Oral

  • ApalutamideDrug

    Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026)

  • DarolutamideDrug

    Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026)

  • DeutenzalutamideDrug

    Oral; available in China only

  • Radium-223Drug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-Free Survival (rPFS)Time frame: From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)
  2. Overall Survival (OS)Time frame: From randomization until death from any cause (up to approximately 33 months)

Locations

151 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Dothan, Alabama · Recruiting

  • Research Site

    Phoenix, Arizona · Withdrawn

  • Research Site

    Duarte, California · Recruiting

  • Research Site

    Irvine, California · Not yet recruiting

  • Research Site

    Newport Beach, California · Recruiting

  • Research Site

    San Francisco, California · Recruiting

  • Research Site

    Aurora, Colorado · Not yet recruiting

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    O'Fallon, Illinois · Not yet recruiting

  • Research Site

    Metairie, Louisiana · Recruiting

  • Research Site

    Westbrook, Maine · Not yet recruiting

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Grand Rapids, Michigan · Not yet recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    Omaha, Nebraska · Recruiting

  • Research Site

    Albuquerque, New Mexico · Not yet recruiting

  • Research Site

    New Hyde Park, New York · Not yet recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Dayton, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Pittsburgh, Pennsylvania · Recruiting

  • Research Site

    Myrtle Beach, South Carolina · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Salt Lake City, Utah · Suspended

  • Research Site

    Tacoma, Washington · Not yet recruiting

  • Research Site

    Darlinghurst, Australia · Not yet recruiting

  • Research Site

    Kurralta Park, Australia · Not yet recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Murdoch, Australia · Not yet recruiting

  • Research Site

    Linz, Austria · Not yet recruiting

  • Research Site

    Salzburg, Austria · Not yet recruiting

  • Research Site

    Vienna, Austria · Not yet recruiting

  • Research Site

    Ghent, Belgium · Not yet recruiting

  • Research Site

    Leuven, Belgium · Not yet recruiting

  • Research Site

    Liège, Belgium · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.